Document is current
Any future updates will be listed below
-
Authors
Hanafin, Patrick
Ho, Yu Liu https://orcid.org/0009-0005-0074-1938
Papathanasiou, Theodoros https://orcid.org/0000-0003-2691-9392
Fulci, Giulia
Sule, Neal
Kremer, Brandon E
Ferron-Brady, Geraldine
-
Funding
Funding for this research was provided by:
GSK
- License Information
-
More Information
Article History
Received: 3 April 2025
Accepted: 21 August 2025
First Online: 16 September 2025
Declarations
:
: Study 207499 and the analyses reported herein were funded by GSK. Drug linker technology licensed from Seagen Inc.; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.
: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady are employees of and hold financial equities in GSK.
: The DREAMM-8 trial protocol and amendments were approved by the appropriate ethics body at each participating institution.
: All patients provided written informed consent before enrollment in DREAMM-8.
: N/A
: GSK makes available anonymized individual participant data and associated documents from interventional clinical studies that evaluate medicines, upon approval of proposals submitted to .
: N/A.
: Conceptualization and design: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady; Data collection and analysis: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady; Writing—review and editing: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady. The first draft of the manuscript was written by Alexus Rivas-John and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
